Arcellx Inc. will participate in the 2026 Tandem Meetings, taking place from February 4-7, 2026, at the Salt Palace Convention Center in Salt Lake City, Utah. The company will present three studies highlighting its D-Domain platform technology and commercial progress for anito-cel in multiple myeloma, including research on its pharmacology, treatment sequencing outcomes, and geographic inequities in CAR T-cell therapy access.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcellx Inc. published the original content used to generate this news brief on January 21, 2026, and is solely responsible for the information contained therein.